Afatinib ‘first line’ for advanced mutation-positive lung cancer

Afatinib should be given as a first-line treatment for Asian patients with advanced, epidermal growth factor receptor mutation-positive, non-small-cell lung cancer, researchers recommend.

Source: MedWire News - Oncology - February 17, 2014 Category: Cancer & Oncology Source Type: news